Exciting study results..

[Don_1213]

A recent study revealed a significant effect of the immunotherapy agent enoblituzumab (try pronouncing that one..) for high-risk prostate cancer patients:

medicalxpress.com/news/2023...

There are a number of other articles about it - the use isn't only in prostate cancer, but it seemed to have the best results in high-risk prostate cancer patients

medicalxpress.com/news/2021...

It seems my medical oncologist was part of the studies - so I'll be chatting with him about it next time we talk.

Good stuff!

[Spyder54]

“Twenty-one patients, or 66%, had an undetectable prostate-specific antigen (PSA) level 12 months following surgery, suggesting that there was no sign of residual disease. Additionally, the drug was well-tolerated overall; no patients had any surgical delays or medical complications during or after the operatio”

Yes, this is very good NEWS!

We must also remember these were very Advanced PCa cases. I saved the article, although I am 2 yrs-4mos since Dx, and 1 yr-5mos since SABR of Prostate. The MAB Drugs seem to hold promise for extension of life, which brings us one step closer to extended remission. Mike